The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy
Open accessAbstract
Objectives: Pompe disease is a progressive metabolic myopathy for which enzyme replacement therapy (ERT) was approved in 2006. While various publications have examined the effects of ERT in classic‐infantile patients and in adults, little has been published on ERT in children with non‐classic presentations. Study design: This prospective study was conducted from June 1999 to May 2015. Seventeen patients from various countries participated. Outcome measures comprised muscle function (6‐minute walk test, quick motor‐function test (QMFT)), muscle strength (hand‐held dynamometry; manual muscle testing), and lung function (FVC sitting and supine). For each outcome measure, we used linear mixed‐effects models to calculate the difference at group level between the start of therapy and 7 years of ERT. Patients’ individual responses over time were also evaluated. Results: Eleven males and six females started ERT at ages between 1.1 and 16.4 years (median 11.9 years); 82% of them carried the common c.‐32‐13T > G GAA gene variant on one allele. At group level, distance walked increased by 7.4 percentage points (p < 0.001) and QMFT scores increased by 9.2 percentage points (p = 0.006). Muscle strength scores seemed to remain stable. Results on lung function were more variable. Patients’ individual data show that the proportion of patients who stabilized or improved during treatment ranged between 56 and 69% for lung function outcomes and between 71 and 93% for muscle strength and muscle function outcomes. Conclusions: We report a positive effect of ERT in patients with childhood Pompe disease at group level. For some patients, new or personalized treatments should be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Given their clinical heterogeneity, finding effective treatments has been a challenge with the only approved therapy, ERT, creating secondary complications from increased survival.232”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [232]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526 · cited 1×
“Multiple testing correction was applied according to the Holm method (Holm 1979).”
MethodATS Statement: Guidelines for the Six-Minute Walk Test
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.166.1.at1102 · Cited by 11,195
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Quanjer, P. H., Stanojevic, S., Cole, T. J., Baur, X., Hall, G. L., Culver, B. H., Enright, P. L., Hankinson, J. L., Ip, M. S. M., Zheng, J., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00080312 · Cited by 5,919 · cited 1×
“…(FVC) was measured in sitting and supine positions according to European Respiratory Society and ATS guidelines, and was presented as a percentage of the predicted FVC, corrected for height, gender and ethnicity (American Thoracic Society/European Respiratory Society 2002; Quanjer et al 2012).”
MethodATS/ERS Statement on Respiratory Muscle Testing
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.166.4.518 · Cited by 2,841
Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease
Kishnani, P. S., Corzo, D., Nicolino, M., Byrne, B., Mandel, H., Hwu, W. L., Leslie, N., Levine, J., Spencer, C., McDonald, M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000251268.41188.04 · Cited by 781 · cited 1×
“ERT has been shown to reverse the hypertrophic cardiomyopathy and increase survival in classic-infantile patients (Van den Hout et al 2000; Kishnani et al 2007).”
Backgroundvan der Ploeg, A. T., & Reuser, A. J. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61555-x · Cited by 756
A Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease
van der Ploeg, A. T., Clemens, P. R., Corzo, D., Escolar, D. M., Florence, J., Groeneveld, G. J., Herson, S., Kishnani, P. S., Laforet, P., Lake, S. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909859 · Cited by 745 · cited 6×
“In addition, patient 16 was included in the international randomized controlled trial (van der Ploeg et al 2010).”
BackgroundResultInfluentialKishnani, P. S., Hwu, W.-L., Mandel, H., Nicolino, M., Yong, F., & Corzo, D. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2005.11.033 · Cited by 598 · cited 1×
“Without enzyme replacement therapy (ERT), these infants usually die within the first year of life (van den Hout et al 2003; Kishnani et al 2006).”
Backgroundvan den Hout, H. M. P., Hop, W., van Diggelen, O. P., Smeitink, J. A. M., Smit, G. P. A., Poll-The, B.-T. T., Bakker, H. D., Loonen, M. C. B., de Klerk, J. B. C., Reuser, A. J. J., et al. (2003) · Pediatrics · doi:10.1542/peds.112.2.332 · Cited by 555 · cited 1×
“Without enzyme replacement therapy (ERT), these infants usually die within the first year of life (van den Hout et al 2003; Kishnani et al 2006).”
Background
Research works printed but not linked: 2
- 1978, Aids to the Examination of the Peripheral Nervous System, Memorandum No. 45
- Core Team R, 2015, R Foundation for Statistical Computing
Cited by
Platt, F. M., d’Azzo, A., Davidson, B. L., Neufeld, E. F., & Tifft, C. J. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0025-4 · Cited by 1,052
Neufeld, E. F. (1991) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.60.070191.001353 · Cited by 900
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“Given their clinical heterogeneity, finding effective treatments has been a challenge with the only approved therapy, ERT, creating secondary complications from increased survival.(232) As the prevalence of these disorders increases with the advent of newborn screening, new therapeutic interventions, such as gene repl…”
BackgroundSemplicini, C., Antonio, M. D., Taouagh, N., Béhin, A., Bouhour, F., Echaniz‐Laguna, A., Magot, A., Nadaj‐Pakleza, A., Orlikowski, D., Sacconi, S., et al. (2020) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12272 · Cited by 63
“The prognosis of classical infantile Pompe disease has been considerably modified by ERT, administered intravenously with dosages ranging from 20 mg/kg/eo week to 40 mg/kg/week.(11,12) In the adult form, a randomized, double-blind, placebo-controlled trial (LOTS), conducted in 90 patients over an 18-month period, show…”
BackgroundPompe disease gene therapy: neural manifestations require consideration of CNS directed therapy
Byrne, B. J., Fuller, D. D., Smith, B. K., Clement, N., Coleman, K., Cleaver, B., Vaught, L., Falk, D. J., McCall, A., & Corti, M. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.05.56 · Cited by 51
Metadata
- Authors
- van der Meijden, J. C., Kruijshaar, M. E., Harlaar, L., Rizopoulos, D., van der Beek, N. A. M. E., & van der Ploeg, A. T.
- Affiliations
- Center for Lysosomal and Metabolic Diseases, Department of Pediatrics Erasmus MC University Medical Center Wytemaweg 80 Rotterdam 3015 CN The Netherlands
- Erasmus MC (NL)
- Center for Lysosomal and Metabolic Diseases, Department of Neurology Erasmus MC University Medical Center Rotterdam the Netherlands
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 2018-03-19
- Volume
- 41
- Issue
- 6
- Pages
- 1205-1214
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- PMC
- PMC6326992
- OpenAlex
- W2789403551
- Cited by
- 37
- References
- 50
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 3 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 4 · 2019: 2 · 2018: 4
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Journal of Inherited Metabolic Disease (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Funders
- University Medical Center Rotterdam
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- Pompe disease, enzyme replacement therapy, muscle function, muscle strength, lung function, long-term follow-up, metabolic myopathies
- MeSH terms
- Walk Test, Adolescent, alpha-Glucosidases, Animals, Child, Child, Preschool, Female, Follow-Up Studies, Glycogen Storage Disease Type II, Humans, Infant, Male, Prospective Studies, Rabbits, Respiratory Function Tests, Linear Models, Treatment Outcome, Internationality, Muscle Strength, Enzyme Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy. https://app.cochat.ai/papers/10.1007/s10545-018-0166-3
- The paper
- van der Meijden, J. C., Kruijshaar, M. E., Harlaar, L., Rizopoulos, D., van der Beek, N. A. M. E., & van der Ploeg, A. T. (2018). Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy. Journal of Inherited Metabolic Disease. https://doi.org/10.1007/s10545-018-0166-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.